DAFNA Capital Management LLC Grows Holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

DAFNA Capital Management LLC increased its stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 85.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,511,374 shares of the company's stock after purchasing an additional 1,160,666 shares during the period. DAFNA Capital Management LLC owned 1.14% of Lineage Cell Therapeutics worth $1,262,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Alyeska Investment Group L.P. acquired a new position in shares of Lineage Cell Therapeutics during the 4th quarter worth about $1,984,000. Renaissance Technologies LLC grew its position in shares of Lineage Cell Therapeutics by 1,058.3% during the 4th quarter. Renaissance Technologies LLC now owns 2,283,072 shares of the company's stock worth $1,147,000 after purchasing an additional 2,085,972 shares in the last quarter. Raffles Associates LP grew its position in shares of Lineage Cell Therapeutics by 21.8% during the 4th quarter. Raffles Associates LP now owns 5,492,088 shares of the company's stock worth $2,760,000 after purchasing an additional 984,307 shares in the last quarter. Defender Capital LLC. boosted its position in shares of Lineage Cell Therapeutics by 19.2% during the 4th quarter. Defender Capital LLC. now owns 5,963,348 shares of the company's stock worth $2,997,000 after acquiring an additional 961,150 shares in the last quarter. Finally, Comerica Bank boosted its position in shares of Lineage Cell Therapeutics by 220.0% during the 4th quarter. Comerica Bank now owns 800,000 shares of the company's stock worth $402,000 after acquiring an additional 550,000 shares in the last quarter. Institutional investors own 62.47% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on LCTX shares. D. Boral Capital reissued a "buy" rating and set a $2.00 target price on shares of Lineage Cell Therapeutics in a research note on Tuesday, March 11th. B. Riley reduced their price objective on shares of Lineage Cell Therapeutics from $4.00 to $3.00 and set a "buy" rating for the company in a report on Friday, March 14th. Finally, HC Wainwright restated a "buy" rating and set a $9.00 price target on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $4.20.

Lineage Cell Therapeutics Stock Performance

NYSEAMERICAN:LCTX traded down $0.02 during midday trading on Tuesday, reaching $0.46. 687,959 shares of the stock traded hands, compared to its average volume of 1,308,151. The business has a 50-day moving average of $0.47 and a two-hundred day moving average of $0.63. The stock has a market capitalization of $100.80 million, a PE ratio of -3.81 and a beta of 1.21. Lineage Cell Therapeutics, Inc. has a 12-month low of $0.37 and a 12-month high of $1.17.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.